Boosting helper immune cells to make HIV vaccines last longer
Harnessing CD4 T follicular helper 1 cells for HIV vaccine efficacy
This work tries to get HIV vaccines to produce stronger, longer-lasting antibody protection by encouraging a specific helper immune cell type.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11145229 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are testing vaccine formulas in rhesus macaques that nudge a type of CD4 helper cell (Tfh1) known to support durable antibody responses. They will compare priming with adjuvanted DNA versus adjuvanted mRNA or unadjuvanted controls, then give protein boosts formulated with ALFQ to reinforce the response. The team will measure antibody levels, quality (avidity), and protection about 20 weeks after the final immunization to see which approach best sustains immunity. Findings will guide whether similar strategies should move into human vaccine trials.
Who could benefit from this research
Good fit: This project is preclinical and currently uses animal models, so it is not enrolling people now; future human trials would likely recruit adults at risk for HIV exposure.
Not a fit: People already living with HIV or those seeking immediate clinical treatment should not expect direct benefit from this preclinical vaccine research.
Why it matters
Potential benefit: If successful, this approach could lead to HIV vaccines that protect people for longer periods and reduce the need for frequent boosters.
How similar studies have performed: Earlier macaque studies from this group have shown that promoting Tfh1 cells can improve antibody persistence and quality, though human effectiveness has not yet been shown.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Iyer, Swaminathan Smita — University of Pittsburgh at Pittsburgh
- Study coordinator: Iyer, Swaminathan Smita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.